Discontinuation report SANDOSTATIN
| Report ID | 154429 |
| Drug Identification Number | 02049392 |
| Brand name | SANDOSTATIN |
| Common or Proper name | SANDOSTATIN MDV 200MG 5ML |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | OCTREOTIDE |
| Strength(s) | 200MCG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 5ML |
| ATC code | H01CB |
| ATC description | HYPOTHALAMIC HORMONES |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-02-28 |
| Actual discontinuation date | 2022-02-14 |
| Remaining supply date | 2023-02-28 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-03-07 | French | Compare |
| v4 | 2022-03-07 | English | Compare |
| v3 | 2022-02-08 | French | Compare |
| v2 | 2022-02-08 | English | Compare |
| v1 | 2022-02-08 | English | Compare |
Showing 1 to 5 of 5